Tigermed hones in on $1.4bn HK secondary listing

By Jonathan Breen
27 Jul 2020

Hangzhou Tigermed Consulting, a biopharmaceutical research and development service provider, has covered books on its secondary public offering in Hong Kong on the first day of taking orders.

Tigermed, which already trades on the ChiNext board of the Shenzhen Stock Exchange, is targeting an enlarged market capitalisation of HK$85.7bn ($11.05bn) from its HKEX listing.

The firm is floating 107.1m primary-H shares, or 12.5% of its enlarged equity capital, at HK$88.00 to HK$100.00 per share. There is ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial